CTOs on the Move

BioMarin

www.biomarin.com

 
BioMarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. We remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. These patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. Time is critical to patients with ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.biomarin.com
  • 770 Lindaro Street
    San Rafael, CA USA 94901
  • Phone: 415.506.6700

Executives

Name Title Contact Details
Shilpa Shroff
Executive Director of Technology Development for Process Science Profile
Robert Baffi
President of Global Manufacturing and Technical Operations Profile
Chris Houlder
Senior Director, Global CyberSecurity Profile
David Shiao
Director - Information Technology Security and Compliance Profile

Funding

BioMarin raised $720M on 08/10/2016

Similar Companies

BioCaptiva

Use this space to add a brief description of your project.

Medicenna Therapeutics Corporation

Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna`s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna`s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna`s IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

Alexander G

Alexander G is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spine Team Texas

Spine Team Texas is a Southlake, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AngioScore

AngioScore is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.